Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 17/20 | 0.66 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28652525 | 1.00 | LOXL2 (0.66) | LOXL2MAOALOXL3KCNH2AOC3 | |
| SCHEMBL28927295 | 0.93 | LOXL2 (0.66) | LOXL2MAOALOXL3KCNH2AOC3 | |
| SCHEMBL19259854 | 0.89 | LOXL2 (0.73) | LOXL2MAOALOXL3KCNH2AOC3 | |
| SCHEMBL29972056 | 0.85 | LOXL2 (0.66) | LOXL2MAOAKCNH2AOC3PDPK1 | |
| SCHEMBL29971096 | 0.81 | LOXL2 (0.58) | LOXL2MAOALOXL3KCNH2AOC3 | |
| SCHEMBL19259777 | 0.81 | LOXL2 (0.73) | LOXL2MAOALOXL3KCNH2AOC3 | |
| SCHEMBL29971316 | 0.80 | LOXL2 (0.68) | LOXL2LOXL3AOC3LOX | |
| SCHEMBL19259830 | 0.80 | LOXL2 (1.00) | LOXL2MAOALOXL3KCNH2AOC3 | |
| SCHEMBL19274275 | 0.79 | LOXL2 (0.65) | LOXL2MAOALOXL3KCNH2AOC3 | |
| SCHEMBL28638854 | 0.79 | LOXL2 (0.52) | LOXL2MAOALOXL3KCNH2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | LOXL2 3/4885MAOA 59/4885LOXL3 2/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | LOXL2 3/4885MAOA 59/4885LOXL3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.